Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:15:26.539Z.
Calculation as of: 2026-10-06T16:15:26.539Z.
Quote observation: 2026-10-06T16:15:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23f55305a71a3950b031d13a123c7a4da2ce3ae96893c1a2d36d58e557527924
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $898.80M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $899.69M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $883.79M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $913.12M | 6.47 | 5.08 | 6.65 | 9.17 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $874.76M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.69M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $935.65M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $859.14M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $946.97M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $844.23M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
5.8
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
